Clinical Trials Browser

Interventional × lazertinib × Thoracic × Clear all

NCT02609776 2026-06-05

CHRYSALIS

Phase 1 Active not recruiting

751 enrolled 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT05498428 2026-06-05

PALOMA-2

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06120140 2026-06-05

COCOON

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06667076 2026-06-05

COPERNICUS

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05663866 2026-06-02

Premedication to Reduce Amivantamab Associated Infusion Related Reactions

Phase 2 Active not recruiting

68 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT04248829 2026-05-28

Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

Phase 3 Completed

393 enrolled 13 charts

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

NCT07586202 2026-05-14

AmiNA

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT04077463 2026-05-08

Chrysalis-2

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04487080 2026-05-08

MARIPOSA

Phase 3 Active not recruiting

1,074 enrolled 13 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT04988295 2026-05-08

MARIPOSA-2

Phase 3 Active not recruiting

776 enrolled 13 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT05388669 2026-05-08

PALOMA-3

Phase 3 Active not recruiting

418 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT06106802 2026-02-23

Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment

Phase 2 Recruiting

Non-Small Cell Lung Cancer Metastatic

NCT06268210 2026-02-09

NeoLazer

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05786430 2026-01-27

LUCAS

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05601973 2026-01-21

AMAZE-lung

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04965090 2025-12-18

A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT05299125 2025-10-01

AMIGO-1

Phase 2 Active not recruiting

Metastatic Non-small Cell Lung Cancers

NCT04075396 2025-04-29

A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 1/2 Completed

29 enrolled 53 charts

Carcinoma, Non-Small-Cell Lung

NCT05338619 2023-09-01

PLATINUM

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT06020989 2023-09-01

CHAMELEON

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05701384 2023-01-27

Lazertinib 160mg in EGFR T790M NSCLC

Phase 2 Unknown

Lung Neoplasms

NCT05477615 2022-07-28

Lazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain Metastases

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05167851 2021-12-22

The Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung